Rocket Pharmaceuticals (RCKT) Total Current Liabilities (2014 - 2026)

Rocket Pharmaceuticals has disclosed Total Current Liabilities across 13 years of filings, most recently posting $24.5 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $24.5 million, down 30.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.5 million (down 30.71% YoY), and the FY2025 annual result was $30.2 million, down 25.75% from the prior year.
• Total Current Liabilities came in at $24.5 million for Q1 2026 at Rocket Pharmaceuticals, down from $30.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $48.5 million in Q4 2023 to a low of $22.6 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $33.5 million (2023), against an average of $34.1 million.
• Peak annual rise in Total Current Liabilities reached 76.7% in 2022, while the deepest fall reached 44.26% in 2022.
• Rocket Pharmaceuticals' Total Current Liabilities stood at $39.2 million in 2022, then increased by 23.84% to $48.5 million in 2023, then retreated by 16.12% to $40.7 million in 2024, then slipped by 25.75% to $30.2 million in 2025, then dropped by 19.0% to $24.5 million in 2026.
• The last three Total Current Liabilities figures came in at $24.5 million (Q1 2026), $30.2 million (Q4 2025), and $31.2 million (Q3 2025), per Business Quant data.